Which meningococcal vaccine is recommended for individuals greater than 2 years old?

Which meningococcal vaccine is recommended for individuals greater than 2 years old?

• A. Menveo
• B. MenQuadfi
• C. Menactra
• D. Bexsero

Answer: (B)

MenQuadfi is recommended for individuals greater than 2 years old as it is designed to protect against four serogroups of Neisseria meningitidis: A, C, W, and Y. This vaccine is utilized in both children and adults to provide broad coverage against meningococcal disease, which can lead to serious conditions like meningitis and septicemia. In contrast, Menveo and Menactra are also meningococcal vaccines that target similar serogroups, but they have specific recommendations regarding age and administration that might limit their use to specific age groups or population settings. For example, Menactra is recommended for children starting at 9 months, whereas Menveo can be given from 2 years old but has slightly different formulations and age recommendations for younger individuals. Bexsero, on the other hand, is a meningococcal group B vaccine and is primarily recommended for different age groups, specifically starting at 10 years of age and not for the same broad population as MenQuadfi. Choosing MenQuadfi aligns with the broader recommendations for vaccination against meningococcal disease in individuals over 2 years of age, making it the most appropriate option in this case.

MenQuadfi is recommended for individuals greater than 2 years old as it is designed to protect against four serogroups of Neisseria meningitidis: A, C, W, and Y. This vaccine is utilized in both children and adults to provide broad coverage against meningococcal disease, which can lead to serious conditions like meningitis and septicemia.

In contrast, Menveo and Menactra are also meningococcal vaccines that target similar serogroups, but they have specific recommendations regarding age and administration that might limit their use to specific age groups or population settings. For example, Menactra is recommended for children starting at 9 months, whereas Menveo can be given from 2 years old but has slightly different formulations and age recommendations for younger individuals.

Bexsero, on the other hand, is a meningococcal group B vaccine and is primarily recommended for different age groups, specifically starting at 10 years of age and not for the same broad population as MenQuadfi.

Choosing MenQuadfi aligns with the broader recommendations for vaccination against meningococcal disease in individuals over 2 years of age, making it the most appropriate option in this case.